TABLE 2.

Noncompartmental pharmacokinetic parameters of moxifloxacin following administration of single ascending doses ranging from 50 to 800 mg^a

Dose (mg [no. of subjects])	AUC (mg · h/liter)	AUCnorm (kg · h/liter)	Cmax (mg/liter)	Cmax,norm (kg/liter)	Tmax (h)b
50 (6)	3.88/1.13 (3.30–4.42)	6.53/1.18 (5.34–8.10)	0.29/1.25 (0.22–0.42)	0.48/1.30 (0.35–0.78)	1.75 (0.50–4.00)
100 (6)	8.51/1.21 (8.06–11.3)	6.18/1.18 (5.08–7.80)	0.59/1.21 (0.46–0.79)	0.43/1.23 (0.31–0.54)	2.00 (1.00–4.00)
200 (6)	15.4/1.20 (12.1–20.8)	6.13/1.13 (5.44–7.57)	1.16/1.35 (0.72–1.54)	0.46/1.27 (0.32–0.57)	2.50 (1.00–3.00)
400 (7)	26.9/1.18 (20.7–33.2)	5.33/1.18 (4.14–6.39)	2.50/1.31 (1.62–3.64)	0.50/1.25 (0.32–0.65)	1.50 (0.50–2.57)
600 (7)	39.9/1.11 (34.1–45.6)	5.45/1.24 (3.75–6.72)	3.19/1.19 (2.41–3.99)	0.44/1.29 (0.31–0.63)	2.50 (0.50–3.00)
800 (7)	59.9/1.24 (42.2–78.1)	6.39/1.22 (4.64–7.76)	4.73/1.16 (3.98–5.61)	0.51/1.16 (0.44–0.68)	3.00 (2.00–4.00)

Mean residence time (h)	t1/2 (h)	V/F (liters/kg)c	CL/F (liters/h)	CLR (liters/h)d	Aeur (%)
16.2/1.17 (12.5–19.9)	11.4/1.11 (9.3–12.4)	2.52/1.15 (2.17–3.22)	12.9/1.13 (11.3–15.2)	2.77/1.22 (0.06–3.38)	20.4/1.15 (17.2–23.7)
17.8/1.13 (15.7–22.2)	12.2/1.11 (11.0–14.6)	2.85/1.13 (2.32–3.11)	11.8/1.21 (8.9–15.3)	2.38/1.25 (1.72–3.26)	18.9/1.34 (10.7–24.6)
17.0/1.11 (14.8–19.9)	14.0/1.14 (12.2–16.7)	3.30/1.14 (2.77–3.87)	13.0/1.20 (9.6–16.6)	2.64/1.25 (2.01–3.52)	19.8/1.16 (16.3–24.0)
14.9/1.14 (11.8–17.9)	13.1/1.06 (12.2–14.6)	3.55/1.23 (2.76–5.10)	14.9/1.18 (12.1–19.3)	3.03/1.17 (2.45–3.75)	20.1/1.20 (15.7–24.7)
14.6/1.18 (12.0–19.0)	12.5/1.14 (10.3–15.0)	3.30/1.12 (2.90–3.95)	15.0/1.11 (13.2–17.6)	2.67/1.10 (2.35–3.08)	17.5/1.16 (14.4–21.8)
14.7/1.13 (12.0–17.3)	12.3/1.13 (9.3–14.3)	2.77/1.19 (2.23–3.41)	13.4/1.24 (10.3–19.0)	2.50/1.28 (1.98–4.14)	18.7/1.25 (13.3–24.7)

^aValues are geometric mean/SD (range) unless indicated otherwise. 

^bValues are median (range). 

^cV/F, volume of distribution during the terminal phase. 

^dCL_R, renal clearance.